Abdala (vaccine)

Abdala, technical name CIGB-66, is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology in Cuba.

[19] As of 28 June 2021, Cuba has not yet released detailed information about the vaccine to the WHO[12] or to the general public via a pre-print or a scientific article.

[23] The Abdala vaccine reportedly consists of a monomeric receptor binding domain subunit, residues 331-530 of the Spike protein of SARS-CoV-2 strain 156 Wuhan-Hu-1, expressed in the yeast Pichia pastoris at 30–40 mg/L fermentation yield.

[23] For animal studies 50 μg of vaccine antigen per dose was adjuvanted with 0.3 mg aluminium hydroxide gel (Alhydrogel) and delivered in 500 μL phosphate buffer.

[26] In April, Nicolás Maduro said that a capacity of 2 million doses per month is hoped to be reached by August or September 2021.

The Institute of Vaccines and Medical Biologicals (IVAC) was named as the focal point for receiving technology transfer.

[38] A wider intervention study with the 1.7 million inhabitants of Havana is expected to start in May with the Abdala and Soberana 2 vaccine.

[47] On 20 September, 2021, The Vietnamese Government has issued a resolution on purchase of 10 million doses of Abdala COVID-19 vaccine.